Here’s an investment idea that starts with large blue-chip companies, but has significant trickle-down potential to at least three smaller, growth companies listed in the UK.
Chances are RSV, or respiratory syncytial virus, which has symptoms similar to the common cold.
It is a highly contagious disease that affects people of all ages, but can be especially dangerous for the elderly.
AIM-listed Synairgen is developing a broad treatment that could potentially fight both flu and RSV Poolbeg Pharma has identified and developed a preclinical agent using artificial intelligence – a world first.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
